Drugs / lymphokine-activated killer cells
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00016042 | Jan 2001 → ? | colorectal cancer, kidney cancer | St. Luke's Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT00005813 | Mar 1997 → Jan 2003 | central nervous system neoplasm | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00814593 | Nov 2008 → Apr 2011 | central nervous system neoplasm | Lisata Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00003067 | Jul 1997 → ? | central nervous system neoplasm | Weill Medical College of Cornell University | Suspended | No outcome recorded |
| Phase 2 | NCT00002535 | Jul 1993 → Jul 2004 | cutaneous melanoma | St. Luke's Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lymphokine-Activated Killer Cells | “NSC-373364 LAK Lymphokine-Activated Killer Cells TIL” NCT00002535 ↗ |
| Known as | LAK | “NSC-373364 LAK Lymphokine-Activated Killer Cells TIL” NCT00002535 ↗2“autologous lymphokine-activated killer (LAK) cells” NCT00814593 ↗ “lymphokine-activated killer (LAK) cells” NCT00003067 ↗ |
| Modality | Cell therapy | “lymphokine-activated killer cells” NCT00002535 ↗ |
| Route | Other | “intracavitary autologous LAK cells plus IL-2” PMID 8625188 ↗ Sep 1995 |